Skip to content

LBRX LBRX Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.1B-43.5%
Alkermes logo
AlkermesALKS
-$165.74M-268%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-$51.18M-100%
Alto Neuroscience logo
Alto NeuroscienceANRO
-$27.09M-63.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6.14M+175%
Opko Health logo
Opko HealthOPK
-$19.31M+44.1%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's operating cash flow?
LBRX (LBRX) reported operating cash flow of -$23.29M in Q1 2026.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.